Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present a 66-year-old asymptomatic man who had incidental brain metastases detected on Ga-PSMA PET/CT, which was later confirmed on biopsy to be prostate adenocarcinoma.
|
30985411 |
2019 |
Adenocarcinoma of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GCPII has been recognized as a neuropeptidase in the central nervous system, as a folate hydrolase participating in absorption of folates in the jejunum and, most importantly, as a prostate-specific membrane antigen that is highly expressed in prostate adenocarcinoma.
|
30844704 |
2019 |
Adenocarcinoma of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PSMA expression in the Hi-Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool.
|
30656716 |
2019 |
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
We presented a promising result of radionuclide therapy using Lu-PSMA and Lu-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation.
|
31693627 |
2019 |
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present a case of a 69-year-old man with history of prostate adenocarcinoma who underwent F-PSMA-1007 PET/CT due to suspected biochemical recurrence.
|
30371591 |
2019 |
Adenocarcinoma of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PSMA overexpression on human prostate adenocarcinoma is also visible with excellent contrast.
|
31120734 |
2019 |
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
We presented a promising result of radionuclide therapy using Lu-PSMA and Lu-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation.
|
31689280 |
2019 |
Adenocarcinoma of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A significant suppression of FOLH1 in NEPC patient samples and AdPC samples with high expression of NE marker genes was observed.
|
30400059 |
2018 |
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report a case of adenocarcinoma prostate treated previously with radical prostatectomy and hormonal therapy who underwent Ga-labeled prostate-specific membrane antigen PET/CT for recurrence evaluation.
|
30004937 |
2018 |
Adenocarcinoma of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA), with folate hydrolase and carboxypeptidase and, internalization activities, is highly expressed in the epithelial cells of the prostate gland and is strongly upregulated in prostatic adenocarcinoma, with elevated expression correlating with, metastasis, progression, and androgen independence.
|
30622933 |
2018 |
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
|
30273204 |
2018 |
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our goal is to evaluate the performance of PSMA and NKX3.1 and compare them with those of prostate-specific antigen (PSA) and prostate specific alkaline phosphatase (PSAP) in the cytological diagnosis of metPA MATERIALS: Cytology specimens from patients with a history of prostate adenocarcinoma at our institution between January 01, 2005 and December 31, 2015 were retrieved.
|
28888085 |
2017 |
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
68Ga PSMA PET/CT in a Rare Case of Metastatic Adenocarcinoma Prostate Presenting as Numb Chin Syndrome.
|
28045729 |
2017 |
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus we have identified delta-catenin (not previously associated with prostatic adenocarcinoma) and confirmed the potential of PSMA as potential candidates for the diagnosis and management of prostate cancer.
|
12115574 |
2002 |
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The use of nested RT-PCR of prostate-specific membrane antigen in blood cells: implications for the detection of haematogenous neoplastic cells in patients with prostate adenocarcinoma.
|
9843660 |
1998 |
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PSM antigen was recognized using the 7E11-C5.3 monoclonal antibody, generated against the LNCaP human prostate adenocarcinoma cell line.
|
9215402 |
1997 |